Translational study and first-in-human (FIH) study design of KH815, a novel dual-payload TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors

Trodelvy (sacituzumab govitecan-hziy) - Gilead

Datroway (datopotamab deruxtecan-dlnk) - Daiichi Sankyo, AstraZeneca

KH815 - Chengdu Kanghong Pharma

F. Ma1; J. Wang1; Y. Zhao2; L. Song3; P. Ren2; L. Qi2; T. Qin3; F. Wu3; X. Ke4

Jul 24, 2025